Researchers make progress toward treatment for dangerous allergies

Oct 09, 2013

New research published in the journal Nature Chemical Biology shows that a group of scientists, led by faculty at the University of Notre Dame, has made concrete progress toward the development of the first-ever inhibitory therapeutic for Type I hypersensitive allergic reactions.

"Our allergy inhibition project is innovative and significant because we brought a novel molecular design approach to selectively inhibit mast cell degranulation—the key event in triggering a food allergic response—which has the potential to improve the quality of life for affected patients," said Basar Bilgicer, assistant professor of chemical and biomolecular engineering at Notre Dame and an investigator in the University's Advanced Diagnostics & Therapeutics initiative.

Allergic reactions are caused when a person's immune system reacts to normally harmless substances in the environment. An allergic reaction can be the source of a simple itch or sneezing; however, Type I hypersensitive can go as far as a life-threatening anaphylactic shock. Mast cells, which are a type of white blood cell, function to protect the body from harmful pathogens such as parasites. In Type I hypersensitive allergic conditions, show a response to otherwise harmless substances (allergens) and result in severe, even potentially lethal, symptoms. The most common examples to Type I hypersensitivity are food allergies, such as to peanuts or shellfish, which affect 15 million Americans and approximately 8 percent of children.

Through the new research, Bilgicer and his group designed a special molecule, called a heterobivalent inhibitor (HBI), which when introduced into a person's bloodstream can, in essence, out-compete allergens like egg or peanut proteins in their race to attach to mast cell receptors.

"Unlike current treatments, such as epinephrine, which help a body endure through an allergic reaction, our HBIs, if introduced into the bloodstream, would actually stop further progression of the allergic reaction from taking place," said Bilgicer.

"We are figuring out the optimum binding sites on the mast cell receptors to attach to, in order to prevent allergens from interacting with them and to prevent the allergic reaction before it even starts in the first place."

The team has demonstrated the effectiveness of their inhibitor molecule on allergic reaction using animal models of allergy. Their next set of targets are a variety of allergens that affect humans—including peanuts, penicillin and dust mites—and they will design HBIs that would be successful inhibitors for each.

Explore further: Selenium compounds boost immune system to fight against cancer

More information: Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation, DOI: 10.1038/nchembio.1358

Related Stories

Egg-allergic children now have no barriers to flu shot

Oct 01, 2013

All children should have flu shots, even if they have an egg allergy, and it's now safe to get them without special precautions. This finding is from the latest update on the safety of the flu vaccine for allergic patients, ...

New target discovered for food allergy treatment

Nov 01, 2012

Researchers at National Jewish Health have discovered a novel target for the treatment of food allergies. Erwin Gelfand, MD, and his colleagues report in the October 2012 issue of the Journal of Allergy and Clinical Immunology that l ...

Recommended for you

Molecules that came in handy for first life on Earth

9 hours ago

For the first time, chemists have successfully produced amino acid-like molecules that all have the same 'handedness', from simple building blocks and in a single test tube. Could this be how life started. ...

Jumping hurdles in the RNA world

Nov 21, 2014

Astrobiologists have shown that the formation of RNA from prebiotic reactions may not be as problematic as scientists once thought.

New computer model sets new precedent in drug discovery

Nov 18, 2014

A major challenge faced by the pharmaceutical industry has been how to rationally design and select protein molecules to create effective biologic drug therapies while reducing unintended side effects - a challenge that has ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.